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Introduction
The basic principles of miniaturized and parallelized ligand-binding assays were ¢rst described in the 1980s in the context of multi-analyte assays and the ambient analyte assay theory. 1 Since then, arrays of synthetic or recombinant proteins and peptides, single framework antibody fragments and monoclonal or polyclonal antibodies on planar surfaces have emerged as important proteomic research tools, and have been successfully applied for the identi¢cation, quanti¢cation and functional analysis of proteins in basic and applied proteome research. 2--16 Common to all these approaches are the requirements for a solid surface (a substrate or solid phase) and a set of immobilized molecules (the probes) that participate in a solid--liquid interaction with a solution of molecules to be investigated (the 'targets'). Arrays are also gaining ground in clinical diagnostics, where this strategy confers a number of potential bene¢ts. These include the possibility of testing a sample in replicate for a large number of analytes simultaneously, with minimal reagent consumption, typically microlitres or nanolitres.
Principles of microarray analysis
A typical microarray experiment is illustrated in Figure 1 . A series of arrays are manufactured by spotting a total of 30 di¡erent antigens in a 6 Â5 array on a suitable surface (e.g. a microscope slide). In this example, the arrays are used to test controls (high and low) and samples of serum from Patients 1 and 2 for the presence of antibodies reactive with the arrayed antigens. Antibody captured at the di¡erent sites is revealed by reaction with an anti-antibody conjugated to a suitable label. Inspection and comparison of the signals at each array location with the results for the high and low controls enable qualitative assessment of the concentration of speci¢c antibody present in each sample. Alternatively, the signal generated at each array location can be measured to derive a quantitative assessment of antibody concentration. A major bene¢t of this analytical strategy is work simpli¢cation, since a sample can be simultaneously tested for 30 di¡erent antibodies using a single analytical device.
Array manufacture
The considerable diversity of arrays that can be produced arises from the fact that proteins or peptides can be attached in series or in parallel by a variety of physical and chemical methods to a range of planar substrates with di¡erent surface architectures, and at di¡ering spot sizes and densities, ranging from the micro to the nano. 17, 18 Table 1 summarizes the variety of components and processes that can be used in the production of microarrays. 19--21 These are described in more detail below.
Substrates
In the context of microarrays, a substrate is the material that provides the surface onto which proteins are immobilized. The substrate o¡ers structural stability for the array and facilitates its handling and manipulation during the various steps in the analytical process. The surface of a substrate is sometimes modi¢ed in order to improve or facilitate protein binding (e.g. gold or polylysine coating). Generally, the substrate is made up of a thin piece of glass, silicon or plastic with dimensions of a few centimetres (e.g. glass microscope slides). Some more specialized substrates include arrays of microelectrodes 22 and microcantilevers. 23 The microtitre plate represents an early example of a macro-sized substrate for array assays. The concept of an array of individual reaction wells has since been extended into micro-(e.g.1536 or 9600 well formats) and nanoscales, including wells formed from silica nanotubes. 24, 25 
Protein deposition and immobilization
The means by which protein is immobilized onto a substrate include di¡erent types of printing process (e.g. contact printing by direct surface contact between the substrate and a delivery mechanism that serves to transfer the samples to the surface, or non-contact printing in which the sample is dropped or sprayed onto the surface). The actual attachment of the protein to the surface of the substrate can be by a⁄nity binding, physical adsorption, gel entrapment, covalent bonding or in situ synthesis. Some of the many substrates that have been adopted for microarrays are listed in Table 1 .
The deposition of sub-nanolitres of proteins on substrate surfaces can be achieved using contact printing Figure 1 Typical microarray results. A 6 Â 5 array of 30 different antigens is used to test for specific antibodies present in two controls (high and low) and two samples from two patients (No. 1 and No. 2). The high and low controls give the expected results, and analysis of the clinical samples reveal that Patient 1 is strongly positive for antibodies against antigens at positions 1, 3, 4, 7 and 23, while Patient 2 is strongly positive for antibodies against antigens at positions 3, 4, 6, 9, 16 and 23 arrayers or non-contact deposition technologies. Contact printing arrayers use tiny needles with or without capillary slots. The protein solution from a microtitre plate is transferred onto the surface of the substrate, by depositing sub-nanolitre volumes directly from the surface of the tip onto the surface. Non-contact deposition technologies employ capillaries or inkjet technology to deposit nanolitre-to-picolitre droplets onto the surface. For example, TopSpott is a microstructured device in which arrays of up to 96 tiny capillaries are directly linked to distinct macroscopic £uid reservoirs. It delivers all proteins in parallel, using a piezo-actuator to dispense microdroplets with volumes down to 1nL from each capillary tip. 26 In addition, micropatterned protein arrays can be produced by photolithographic methods, 27 scanning probe-based lithography 28 or soft lithography technologies such as microcontact printing. 29, 30 Another emerging technology for array fabrication is based on mass spectrometry. Electrospray deposition of protein solutions on slightly conductive aluminized plastic surfaces has been used to assemble groups of 1200 identical microarrays (0.6 Â 0.6 mm) consisting of 28 di¡erent protein antigens and allergens deposited as 30--40 mm diameter spots. 31, 32 Another type of mass spectrometry-based fabrication method is soft-landing mass spectrometry. 33, 34 In this technique, multiplyprotonated proteins of particular mass and charge (m/z) are selected from electrospray ionized (ESI) protein mixtures and sequentially landed in m/z order at di¡erent positions on a surface (e.g. gold) to form a microarray. Limitations of this method include the length of time required to deposit signi¢cant amounts of protein and possible loss of biological activity during the ESI process. However, some enzymes, including lysozyme and trypsin, have been successfully arrayed without loss of activity.
In situ synthesis as a method of preparing a microarray is receiving increasing attention. Synthesis can be accomplished by photolithography using a photoremovable protection group and photomasks to de¢ne synthesis areas. 27 An alternative method is based on mask-less photolithography in which a digital micromirror array is used to de-protect areas on a substrate at which amino acid-by-amino acid synthesis of a polypeptide will occur. 35 While most microarrays have been fabricated with spot dimensions in the micrometer scale, nanotechnology is now being exploited to make experimental arrays that have nanometer-sized spots. A key technology is dip pen nanolithography, in which an atomic force microscope tip coated with a protein prints the pattern of proteins onto a suitable surface (e.g. gold, silver, aluminium, titanium dioxide, silica, nickel oxide). 36--39 Protein patterns printed may be as tiny as $10 nm in size.
Proteins can be immobilized onto substrates using non-covalent surface interactions with hydrophobic (e.g. nitrocellulose; polystyrene) or positively charged (e.g. poly-lysine; aminosilane) surfaces, with wellestablished applications in conventional immunoassay and Western blotting. Membranes have a large surface area and, consequently, high protein-binding capacity, but su¡er from potential background problems due to auto£uorescence. In contrast, glass slides can be prepared as ultra-£at devices with a minimal degree of auto£uorescence. However, glass surfaces show poor protein-binding capacity, and surface modi¢cations are necessary to optimize protein binding, e.g. by aminosilane, poly-lysine or aldehyde surface activation. A variety of sophisticated surface chemistries have been developed to meet the speci¢c needs for immobilizing and stabilizing proteins on microarrays. These include an appropriate surface chemistry that enables the attachment of proteins in a functional state and in a de¢ned orientation with minimal non-speci¢c protein binding (e.g. 3D structures such as hydrogel modi¢cations, or surfaces well known from surface plasmon resonance [SPR] immunoassays). Besides non-covalent and covalent attachment of proteins, spe-ci¢c bimolecular interactions (e.g. streptavidin/biotin; His-tag/nickel-chelates and glutathione/glutathione S-transferase) have also been used successfully to immobilize proteins in a microarray format on surfaces. A recent a⁄nity-based method uses calixcrown-5 derivatives. 40 An aldehyde or thiol-activated calixcrown derivative is attached to the substrate surface. Proteins can then bind to the immobilized calixcrown via electrostatic interactions between the ionized amide groups on the protein and the crown moiety. Studies with immunoglobulin G (IgG) antibodies (anti-C-reactive protein (anti-CRP)) showed that the antibodies formed a monolayer and were oriented vertically, with the Fc domain bound to the surface calixcrown molecules.
Several studies have compared di¡erent types of experimental and commercial substrates. Macroporous, microporous and planar silicon (with or without a nitrocellulose coating) have been compared with ¢ve commercial surfaces with respect to biocompatibility, binding capacity and reproducibility. 41 A nitrocellulose-coated macroporous silicon was found to have properties that were equal or superior to those of any commercial substrates for immobilizing the single-chain Fv antibodies used in the study. Studies comparing prototype substrates with dendrimer or epoxy-activated polyethylene glycol (PEG) layers and various commercial slides (polystyrene, nitrocellulose or amine or epoxy activated surfaces) found the dendrimer and epoxy-activated PEG slides to be superior to the other surfaces tested. 42 
Preservation of biological reactivity
An overriding consideration in array manufacture is the preservation of the biological reactivity of the arrayed protein (e.g. antigen--antibody binding). General strategies to preserve the integrity of the protein include careful control of temperature and humidity during manufacturing and storage, and protection of the protein during the arraying step by adding, for example, sucrose and trehaloses to the protein solutions. 31 Other strategies create de¢ned surface layers that are designed to immobilize proteins in an environment that is non-denaturing and inert to non-speci¢c binding (e.g. PEG; a copolymer of N,N-dimethylacrylamide-N,N-acryloyloxysuccinimide and [3-(methacryloyloxy)propyl]trimethyloxysilyl; polyvinyl alcohol 43, 44 ) and conducive to ligand binding (e.g. a three-dimensional hydrogel ¢lm). 45 Another strategy to preserve the biological activity of a protein is to design an immobilization method that orientates the protein in a controlled manner, as this is known to increase binding capacity. 46 This can be achieved by a bioa⁄nity-based immobilization procedure in which a DNA or biotin tag on a protein determines the orientation of the immobilized protein either via hybridization to surface DNA or by binding to surface streptavidin. A comparison of direct spotting, DNA-directed and biotin-directed immobilization of antibodies on glass supports, found superior performance with the DNA-directed immobilization strategy in terms of spot homogeneity and inter-experiment reproducibility. 47 
Non-specific binding
Another key consideration for protein array-based assays is non-speci¢c binding. Strategies to minimize this include, for example, the fabrication of two-dimensional patterns of hydrophobic regions that separate immobilized protein areas. 48 This is accomplished by ¢rst patterning a photoresist-covered silicon wafer with the desired array architecture. This is then covered with a thin ¢lm of a hydrophobic material (e.g. CYTOPt), and the photoresist and overlying CYTOPt are then removed to reveal a hydrophobic pattern. The naked silicon areas are next oxidized and activated for subsequent protein coupling using 3-aminopropyltriethoxysilane and glutaraldehyde. In order to reduce non-speci¢c binding, arrays are frequently treated with PEG. The protein resistance of this molecule can be combined with speci¢c bioreactivity by preparing poly(L-lysine)-grafted poly(ethylene glycol) polymers. Monolayers of a biotinylated derivative of this polymer on a titanium dioxide substrate were e¡ective for capturing streptavidin and showed minimal non-speci¢c binding. 49 
Assay design
Protein microarray assays can be classi¢ed into two categories: (1) speci¢c protein assays for proteomic applications and (2) functional protein assays that probe the functional activity of a protein or set of proteins. The ¢rst category can be further subdivided into forward-and reverse-phase protein microarrays (Figure 2 ), depending on how the sample is applied. For forward-phase protein arrays, the sample is applied to an array of immobilized capture proteins so that di¡erent analytes can be analysed simultaneously. In the reverse-phase format, the di¡erent samples are immobilized as an array format and are screened for the presence or absence of one distinct target protein by applying an appropriate reagent to the array.
Functional protein assays analyse speci¢c protein functions such as protein--protein, enzyme--substrate, protein--DNA, protein--oligosaccharide and protein-drug interactions. Low-and high-density arrays of proteins, protein domains, peptides and small molecules have been used to study the binding of a variety of biomolecules, including DNA, RNA, small chemical ligands and proteins, to immobilized binding partners.
Simple binding of a labelled molecule to an arrayed protein, as well as sandwich and competitive assay designs, is employed in protein microarray assays. Protein concentrations in samples can range over several orders of magnitude, and available antibodies can have a range of a⁄nities, complicating the design of protein microarray assays. Competitive displacement assays, in which proteins in a sample compete with labelled proteins in a reference preparation for binding to arrayed antibodies, have been advocated as a way of overcoming these problems. 50 This strategy compares the displacement capabilities of a series of samples with each other versus the labelled reference sample. The assay was found to be tolerant to protein concentrations and liquid-handling errors. Studies with ovary lysates analysed as1:1or10:1mixtures with the labelled reference sample revealed the same set of highly di¡erentially expressed proteins. An alternative assay method that is useful for protein pro¢ling uses a two-colour detection strategy (e.g. Cy3 [green] and Cy5 [red] £uorescent dye labels) analogous to the strategy developed for mRNA expression pro¢ling ( Figure 3 ). 51, 52 
Labels and detection reactions
The labels and detection reactions used in conventional immunoassays are suitable for array-based assays, and include enzymes (with detection by £uorescence, time-resolved £uorescence, colorimetry or chemiluminescence) and oligonucleotides (Rolling Circle Ampli¢cation detection scheme). More recently, 20-nm diameter gold-labelled antibody or streptavidin has been used to detect species bound to a protein array. 53 The bound label was quantitated by counting the number of gold particles in images generated by scanning electron microscopy. The gold label was found to be about 50-fold more sensitive than £uorescence detection of a Cy-3 label.
Label-free methods
Various label-free assay designs have also been devised for use with protein micro-or nanoarrays. An atomic force microscope (contact or tapping mode) can measure protein binding directly by sensing the change in height at an array location due to capture of the analyte. 54 SPR imaging provides a multiplexed format for detection of analyte binding to an array on a gold surface. 55--58 Illumination of the array surface leads to a coupling with electrons in the gold surface to form a surface plasmon. Increases in the refractive index, due to capture of analyte by arrayed capture molecules, modulate the angle of incidence at which the maximum amount of coupling occurs, thus reduces the intensity of re£ected light. These changes can be correlated with analyte concentration, and this method has been used successfully in assays for cytokines. 57 SPR imaging has also been applied to screening of protein-protein interaction inhibitors (e.g. E7 protein from human papillomavirus and retinoblastoma tumour suppressor RB). Methods to improve the sensitivity of an SPR-monitored microarray sandwich immunoassay have been devised based on a horseradish peroxidasecatalysed precipitation reaction. Precipitation catalysed by captured peroxidase conjugate induces a shift in the SPR angle and improves detection. Human interferon-gamma has been measured using this technique at a concentration of 0.01ng/mL. 59 Another type of label-free protein microarray assay has been devised using self-sensing piezo-resistive micro-cantilevers. 60, 61 Antigen--antibody binding causes the cantilever to bend, causing a change in the resistance of the piezo-resistive layer, which can be sensed electrically. This type of sensor has been used to detect prostate-speci¢c antigen (PSA) and C-reactive protein (CRP) to at least10 mg/L. 62 Generally, only small arrays of cantilevers have been produced, and individual cantilevers are used for reference and test sites. Nevertheless, the potential exists for large multiplexed arrays for multi-protein testing. Electrochemical impedance measurements also provide a route to label-free protein microarray assays. 63 This has been successfully demonstrated in model studies using di¡erent antigens (human IgG, rat IgG, human globin, bovine serum albumin) immobilized on an array of gold electrodes to detect the respective antibodies.
Pre-analytical factors
The pre-analytical phase of an analytical procedure includes all aspects of patient preparation, specimen collection and the processing of the specimen prior to analysis. Analytical results can be compromised by various pre-analytical factors including the quality of the reagents immobilized on the microarray, detection reagents used in the detection reaction, and the integrity of the sample.
Pre-analytical requirements for specimens for microarray analysis are no di¡erent from those for any other type of clinical specimen, and include correct specimen collection procedures (e.g. correct patient identi¢cation, appropriate preservative) followed by prompt transport and storage under conditions that will not be detrimental to specimen integrity. A recent study used surface-enhanced laser desorption/ionization mass spectrometry (SELDI) to examine lowmolecular-weight protein pro¢les in blood samples processed in di¡erent blood collection tubes and at di¡erent times after sampling (immediate to 24 h). 64 Results of this study revealed considerable variation in the pro¢les depending on the elapsed time and the type of tube used to collect the blood sample, providing a cautionary note for interpretation of protein pro¢le data. Other studies have noted the adverse in£uence of storage for as little as 2 h at room temperature on plasma protein pro¢les. 65 Changes were attributed in part to degradation by proteases present in the sample. Studies with urine samples have highlighted the di¡erences in protein patterns in ¢rst-void versus midstream urine samples from women and the confounding e¡ect of blood in urine. 66 In view of the e¡ects of collection and storage, it has been suggested that rigorous standards should be speci¢ed for the time and temperature of all phases of specimen collection and processing (including clotting, centrifuging, aliquoting, freezing, and thawing), if meaningful and comparable data are to be produced. 65 
Substrate

Analytical factors
The analytical phase of a clinical assay comprises all the procedures and reagents involved in the analysis of the sample. 67 Factors perturbing the analytical procedure can contribute to inaccuracy and imprecision and include aberrant reactivity of reagents or regions of a microarray, and changes in reaction conditions. Analytical failure for a microarray can be catastrophic as many reagents or samples are combined in a single device. Microarray analysis thus presents more complex issues than those usually encountered in conventional testing for one analyte in a single sample. Various additional safeguards have, therefore, been implemented to control and assess analytical factors that might compromise results from a microarray. These include replicate analyses (up to 10 replicates on one array, adjacent duplicates on two di¡erent arrays or duplicate spots in di¡erent regions of the same array), and inclusion of multiple controls on each array. These include a blank control, non-speci¢c binding controls, negative and positive controls, controls to test the binding of key assay reagents and bu¡er spots (on which no signal should be detectable) to assess cross-contamination during printing.
Analytical performance of microarrays is assessed and validated with respect to standard assay parameters, including within-array and between-array imprecision (achievable intra-assay imprecision typically o10% and inter-assay imprecision o20%), linearity, analytical speci¢city (e.g. e¡ects of interfering substances, cross-reactivity of the antibody used in the assay), recovery, limit of detection and comparison with a reference method.
Data acquisition and processing
The amount of data generated in microarray experiments poses signi¢cant challenges for the laboratory. Various software packages have been used for spot identi¢cation and quantitation of digital images derived from measurement of signals (typically £uorescence) on protein microarrays. These include P-SCANt, 68 GenePixt (Axon Laboratories), 69 Image-Quantt (Molecular Dynamics), 70 QuantArrayt (Packard), 71 GeneTACt (Genomic Solutions) 72 and arrayWoRxt (Applied Precision). 73 After scanning of these signals is complete, it is typically necessary to orientate the resulting image in order to link the scanned signal correctly to the identity of the spotted reagents or sample. Placing reference features, or landmarks, on an array usually ensures unambiguous orientation.Various materials have been used to create these features, including Cy3-labelled or biotinylated protein. 72, 74 Following con¢rmation of array orientation and spot identi¢cation, spot quantitation is undertaken. Signal intensity is usually estimated using either the total integrated or average spot intensity. It is important to correct for any background contribution, which can be estimated using the median pixel intensity surrounding the spot, 69 and subtracted from an average intensity to yield the corrected estimate. This approach corrects for any general background signal, but more substantial defects may require elimination of a¡ected array spots from further analysis and consideration. 72 Background-corrected values can then be ¢ltered using an estimated threshold of detection in order to ensure that only analytes with su⁄ciently robust signal are considered for further processing. 75 One of the many analytical concerns for microarrays is intra-and inter-array variation due to di¡erences in the amount of protein in each location on the array. This can a¡ect the comparability of data generated from di¡erent arrays. One useful strategy to overcome this problem involves measurement of the protein concentration in the spots on the array and use of this value to normalize the signal from the relevant spot (intra-array normalization). 68,76--78 One such approach has utilized 16 identical control features on each array from which a median signal value can be obtained and then used to normalize data between arrays. 74 Another normalization strategy employs a control reagent that is added to the sample. Biotinylated bovine serum albumin, for example, has been added to samples and detected via its binding to an anti-BSA spot on the array and to a streptavidin--phycoerythrin reagent. 79 
Commercially available microarray assays
Although the routine clinical use of microarray technology is still in its early stages, di¡erent types of protein microarrays are now available commercially from a number of companies (Appendix A). Those developing protein interaction biochips have recently been surveyed, 80 and general information can also be found on-line (www.biochipnet.de).
The disposable Mastpettet Allergen antibody test, which uses an array of allergen-coated threads, is an early example of a multiplexed assay based on a protein array. 81 However, the ¢rst commercial clinical analyser to use a planar protein array is the Evidencet (Randox Laboratories Ltd, N Ireland). 82 This analyser uses a 9 Â7 mm silanized aluminium oxide substrate (a biochip) with speci¢c ligands (antibodies or antigens) attached at pre-de¢ned sites on the surface. The number of test sites per biochip can be up to 100 and the analyser has a throughput of up to 2000 tests/h. The chip is used for both competitive and sandwich enzyme immunoassays. Bound horseradish peroxidase label is detected using a chemiluminescence detection reaction. A charge-coupled device imaging system simultaneously measures light emission signals for the full array of tests on each chip. The current range of arrays includes multi-analyte panels for the analysis of free thyroid hormones, total thyroid hormones, reproductive hormones, tumour markers including PSA, cytokines and growth factors, cardiac markers, and drugs of abuse.
Speci¢c bene¢ts identi¢ed for this mode of analysis include reduced sample and reagent volume, single multi-analyte reagents and retrospective processing.
Retrospective processing was also a feature of the multi-channel analysers used for biochemical pro¢ling in the 1970s. While retrieving a suppressed result is a labour-saving alternative to an add-on test, suppression of results of non-requested tests that indicate the presence of disease or dysfunction poses an ethical dilemma. In the past, such suppression of results has led to action by patients against health-care providers, and the same problem may plague this option for microarray assays.
In the research setting, most microarray testing has been directed towards biomarker discovery, based on the assumption that more clinically useful markers of disease are present among the many proteins present in cells or in the extracellular milieu. However, protein-screening methods, whether by two-dimensional electrophoresis or microarray, have not as yet identi¢ed many new markers. However, some promising proteomic studies using plasma of ovarian and breast cancer patients have identi¢ed cytosolic serine hydroxymethyl transferase,T-box transcription factor 3 and utrophin as markers that may be useful as components of multi-parameter monitoring of these malignancies. 83 Similar studies in normal and malignant colonic epithelium suggest that alpha-defensins may be useful as serum markers in colorectal cancer. 84 A further belief, particularly in cancer diagnosis, is that very few single protein markers remain to be discovered and that the future of protein markers is instead in combining multiple protein markers to improve diagnostic power, as has been demonstrated by the combination of three serum markers (IL-18, FGF-2 and CA125) associated with epithelial ovarian cancer, thereby achieving higher speci¢city compared with that of CA125 alone. 85 
Quality control
A detailed consideration of quality control (QC) issues is essential for the translation of protein microarray approaches into the clinical laboratory tests. QC of protein microarrays must include consideration of the reproducibility of spotting during array construction, the reproducibility of analyte detection, and the possibility of interferences from sample matrix or other analytes. As discussed above, many of these issues can be addressed through proper design of the measurement device. The possible adverse e¡ects of spot-to-spot variability, for example, has been controlled by replicate spotting of the same analytical reagent, using four or 16 replicates. 86, 87 A more signi¢cant challenge to the use of protein microarrays or other highly multiplexed assays in the clinical laboratory is that conventional procedures for daily QC of quantitative assays are likely to be impracticable for many microarray assay formats. In particular, the practice of running high-and low-range controls for each analyte becomes unwieldy when hundreds of analytes are involved. While it may be tempting to prepare a complex mix of all analytes at low and high concentrations for QC, whether this inappropriately alters the measurement matrix should be considered. It is also unclear how one should treat such QC results for highly multiplexed devices. For example, a failure of QC measures for some, but not all, analytes raises the issue of whether results from the entire device should be discarded, or whether reporting a subset of values is appropriate. The intended clinical utilization of the resulting data may provide some guidance in these situations.
An alternative approach to QC of protein microarrays would be to treat the protein microarray as a single test rather than as a multiplex of quantitative measurements. Much current interest surrounds the idea of pattern-based diagnostic assays, and the global pattern derived from a protein microarray may be su⁄cient to distinguish between a small number of disease states. In this case, however, it will be necessary to carefully consider the strengths and weaknesses of various bioinformatics algorithms with respect to their e¡ect on overall test robustness and quality. Such an approach would indicate that measurements of individual analytes from a multiplex device should not be reported unless those individual analytes had been validated using QC procedures of equivalent rigour to those applied to any other quantitative assay in the clinical laboratory. Clearly, substantial further work on this issue is needed.
Finally, it should be noted that the di⁄culties inherent in QC of highly multiplexed assays do not a¡ect all protein microarray formats equally. In particular, 'reverse-phase'protein microarrays, in which increased throughput is achieved by parallel measurement of arrayed samples containing the analyte of interest together with similarly arrayed control analytes, may contain su⁄cient internal controls to assure the reliability of their individual measurements. While these arrays measure only a single analyte, the large number of samples arrayed may still make it feasible to pro¢le large numbers of analytes on large numbers of samples within a clinical laboratory time scale.
Conclusions
The emergence of protein microarrays and associated developments in functional proteomics 88 provide opportunities for clinical laboratories to expand their test repertoire and develop new types of tests for groups of proteins. However, implementation of microarray analysis presents a series of new challenges, including how best to QC multiple simultaneous assays on a single analytical device. The ultimate role of such testing in the routine clinical laboratory remains to be determined.
